We are live on ! Find out more
EVOK

Evoke Pharma

Delisted

EVOK was delisted on the 16th of December, 2025.

21 hedge funds and large institutions have $7.02M invested in Evoke Pharma in 2017 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 0 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more capital invested

Capital invested by funds: $5.07M → $7.02M (+$1.95M)

0.01% more ownership

Funds ownership: 0.09%0.09% (+0.01%)

0% more funds holding

Funds holding: 2121 (0)

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

Holders
21
Holders Change
Holders Change %
0%
% of All Funds
0.52%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
4
Increased
5
Reduced
Closed
4
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
SFM
1
Sphera Funds Management
Israel
$1.91M +$190K +493 +14%
Vanguard Group
2
Vanguard Group
Pennsylvania
$1.75M
SOMRS
3
State of Michigan Retirement System
Michigan
$1.34M
KCM
4
Knoll Capital Management
Florida
$752K +$134K +348 +29%
BlackRock
5
BlackRock
New York
$209K +$3.86K +10 +2%
Millennium Management
6
Millennium Management
New York
$183K +$147K +381 New
VF
7
Virtu Financial
New York
$132K +$106K +274 New
California Public Employees Retirement System
8
California Public Employees Retirement System
California
$123K
Commonwealth Equity Services
9
Commonwealth Equity Services
Massachusetts
$100K
Northern Trust
10
Northern Trust
Illinois
$98K
Bank of New York Mellon
11
Bank of New York Mellon
New York
$83K
Geode Capital Management
12
Geode Capital Management
Massachusetts
$76K
PNC Financial Services Group
13
PNC Financial Services Group
Pennsylvania
$60K
UCFA
14
United Capital Financial Advisors
Texas
$52K
TSS
15
Two Sigma Securities
New York
$37K +$29.7K +77 New
FM
16
Family Management
New York
$35K
Bank of America
17
Bank of America
North Carolina
$33K
Wells Fargo
18
Wells Fargo
California
$27K +$8.11K +21 +60%
Morgan Stanley
19
Morgan Stanley
New York
$20K +$6.56K +17 +71%
UBS Group
20
UBS Group
Switzerland
$7K
Citigroup
21
Citigroup
New York
$2K +$1.16K +3 New
PM
22
Precept Management
Texas
-$243K -660 Closed
ARTA
23
A.R.T. Advisors
New York
-$39K -107 Closed
AIM
24
Acrospire Investment Management
Illinois
-$6K -17 Closed

EVOK Hedge Fund Activity: Q3 2017 in Review

21 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q3 2017, worth a combined $7.02M — up 38% from $5.07M a quarter earlier.

Fund positioning in EVOK was balanced in Q3 2017: 4 funds opened new positions, 4 closed out, 5 added to existing stakes and 0 trimmed.

The largest buyer was Sphera Funds Management, adding an estimated $190K. The largest seller was Precept Management, exiting entirely with an estimated $243K sold.

  • 21 institutional investors held Evoke Pharma (EVOK) as of Q3 2017, unchanged from Q2 2017.
  • Funds reported $7.02M of Evoke Pharma stock for Q3 2017, up 38% quarter-over-quarter.
  • 4 funds opened new Evoke Pharma positions in Q3 2017 and 4 closed out, a net change of 0 holders.
  • The largest Evoke Pharma buyer in Q3 2017 was Sphera Funds Management, an estimated $190K added.
  • The largest Evoke Pharma seller in Q3 2017 was Precept Management, an estimated $243K sold.

Based on aggregated 13F filings for Q3 2017.